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Background: Endobronchial ultrasound-guided transbronchial nee-
dle aspiration (EBUS-TBNA) is a minimally invasive modality with
a high diagnostic yield for mediastinal lymph node staging of
patients with lung cancer. Although limited to the use of needle
aspiration during EBUS-TBNA, aspirates has been shown to be
useful for molecular analysis. However, the ideal methodology of
the specimen handling during EBUS-TBNA has not been described.
Methods: Based on our institutional experience and review of the
literature, we describe the optimal methodology for multidirectional
analysis of EBUS-TBNA samples.
Results: EBUS-TBNA specimens can be used for molecular anal-
ysis such as epidermal growth factor receptor (EGFR), Anaplastic
lymphoma kinase (ALK) and V-Ki-ras2 Kirsten rat sarcoma viral
oncogene homolog (KRAS) mutations when processed properly.
Rapid on-site cytology is invaluable during the assessment of the
aspirated during EBUS-TBNA.
Discussion: Obtaining adequate samples through a non-surgical biopsy
technique for pathologic diagnosis as well as molecular analysis will be
of immediate importance for personalized management of lung cancer.
EBUS-TBNA is an ideal approach that allows combined pathological
and molecular analysis of metastatic lymph nodes.
Key Words: Endobronchial ultrasound-guided transbronchial nee-
dle aspiration, Microsampling, Molecular testing.
(J Thorac Oncol. 2011;6: 203–206)
The importance of molecular testing in thoracic malignan-cies is well established. Fluorescence in situ hybridization
analysis in lymphoma and epidermal growth factor receptor
(EGFR) mutation assessment in lung cancer have already
become a routine practice in some centers in addition to tissue
diagnosis. Adequate tissue sampling by minimally invasive
nonsurgical procedures for molecular testing is available in a
limited number of centers. Nonsurgical modalities for obtain-
ing tumor specimens are particularly important for the man-
agement of patients with lung cancer, because the majority of
the patients will have advanced disease at the time of first
presentation and, therefore, not eligible for surgery. Endo-
bronchial ultrasound-guided transbronchial needle aspiration
(EBUS-TBNA) contributes to the resolution of this issue,
because samples obtained by EBUS-TBNA can be used for
multiple molecular testing. This report reviews and suggests
optimal methodology of EBUS-TBNA specimen handling to





The convex probe EBUS (BF-UC180F, Olympus, To-
kyo, Japan) used is integrated with a convex probe transducer
(7.5 MHz) on the tip of the bronchoscope that scans parallel
to the insertion direction of the bronchoscope. The ultrasound
images are processed using a dedicated ultrasound scanner
(Olympus, EU-ME1). A dedicated 22-gauge or 21-gauge
needle can be used to perform TBNA (NA-201SX-4022,
NA-201SX-4021, Olympus).
Lymph Node Sampling
After penetration in to the lymph node, the internal
stylet is used to clean out the internal lumen, which may
become clogged with bronchial membrane. The internal
stylet is then removed. Negative pressure can be applied with
a syringe on demand. The needle is usually moved back and
forth inside the lesion of interest 10 to 15 times over 30 to 60
seconds. The needle is then withdrawn into the catheter and
removed from the bronchoscope, and the internal stylet is
used once again to push out the aspirated material.1 With a
cytologist available for rapid on-site cytologic evaluation of
the aspirates, TBNA is continued until adequate sampling is
confirmed. Without rapid on-site cytology, it has been re-
ported that three aspirations per lymph node station or two
aspiration with one tissue core is recommended.2
Specimen Handling and Sample Preparation
for Molecular Testing
The aspirated material is pushed out on to the slide
glass. The core is then placed on a filter paper to absorb
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excess blood. Part of the core can be freshly stored using
stabilizing solutions for extraction of RNA. We have used the
Allprotect Tissue Reagent (Qiagen, Dusseldorf, Germany)
following the manufacturer’s instructions with excellent re-
sults, although other products may serve the same function.
The tissue processed with the filter paper is fixed with 10%
neutral buffered formalin, and a formalin-fixed paraffin-
embedded (FFPE) sample is made. The remaining material is
smeared onto glass slides for both air-dried smears and
immediately fixed with 95% ethanol smears. The air-dried
smears are stained by Diff-Quik staining for rapid on-site
cytology or Giemsa stain solution. The ethanol-fixed smears
are sent for Papanicolaou staining. In addition, the needle is
rinsed into a tube containing normal saline for flow cytometry
and/or microbacterial examination. This is further centrifuged
for preparing cell pellet for DNA and/or RNA extraction. The
FFPE samples are usually stained with hematoxylin and eosin
for histologic diagnosis. In some cases, immunohistochemis-
try can be performed if needed. The FFPE sample can be used
for several kinds of in situ hybridization. In addition, DNA
and/or RNA can also be extracted from FFPE samples that
are applicable for genetic analysis (Fig. 1). The successful
histologic diagnostic rate has been reported to range from
65.1 to 81.0%.3,4 Using this technique, the success rate of
obtaining histologic cores when lymph node metastasis is
present is assumed to be more than 80%.
DISCUSSION
EBUS-TBNA has been shown to have a high diagnostic
yield for mediastinal lymph node staging in patients with lung
cancer.5 In addition, samples obtained by this minimally
invasive techniques have been used for molecular analysis.6,7
To improve the yield of EBUS-TBNA, it is important to
optimize the methodology of specimen handling during the
procedure. For cytologic evaluation, smears can be processed
by air-dry method and ethanol fixation.8 Histologic cores can
be used to make FFPE samples for histologic diagnosis,
which would enable pathologists to perform immunohisto-
chemistry.3 Flow cytometry and in situ hybridization are
extremely helpful for the assessment of lymphoma (Fig. 2).8
Molecular testing has been highlighted for the manage-
ment of patients with lung cancer, especially in directing
targeted therapy with EGFR tyrosine kinase inhibitors.9,10
EGFR gene mutation assessment and other molecular mark-
ers, such as ALK fusion gene alteration, are of importance for
current management decisions.11 Furthermore, there is a pos-
sibility of genetic difference between the primary tumor and
metastatic sites because of the tumor heterogeneity.12,13 Mo-
lecular assessment of metastatic sites (lymph nodes) by
EBUS-TBNA may lead to optimal treatment of patients with
advanced lung cancer (Fig. 2).
The development of a safe and precise modality that
enables the acquisition of sufficient amount of high-quality
FIGURE 1. Multidirectional analysis of EBUS-TBNA samples. Cytologic smears are prepared for both air-dry smear and 95%
ethanol-fixed smear. The histologic core is partially fixed in 10% formalin and the rest stored in 80°C. The TBNA needle is
washed with saline and used for cell block and molecular testing. EBUS-TBNA, endobronchial ultrasound-guided transbron-
chial needle aspiration.
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tissue without surgery has become increasingly important in
the molecularly targeted therapy era. EBUS-TBNA is an
ideal approach that allows molecular analysis of metastatic
lymph nodes in patients with lung cancer. Combined molec-
ular and pathologic analyses of the specimen obtained by
EBUS-TBNA will aid in the optimal management of patients
with lung cancer and preclude the need for more invasive
diagnostic tests.
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